Cargando…

Platinum Resistance in Ovarian Cancer: Role of DNA Repair

Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. It is initially responsive to cisplatin and carboplatin, two DNA damaging agents used in first line therapy. However, almost invariably, patients relapse with a tumor resistant to subsequent treatment with platinum containing d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Damia, Giovanna, Broggini, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357127/ https://www.ncbi.nlm.nih.gov/pubmed/30669514 http://dx.doi.org/10.3390/cancers11010119

Ejemplares similares

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
por: Ricci, Francesca, et al.
Publicado: (2017)

DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?
por: Stefanou, Dimitra T., et al.
Publicado: (2021)

The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
por: Rulli, Eliana, et al.
Publicado: (2016)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
por: Ricci, Francesca, et al.
Publicado: (2019)

Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer
por: Sassu, Carolina Maria, et al.
Publicado: (2021)

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts
por: Guffanti, Federica, et al.
Publicado: (2018)

Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells
por: Pastò, Anna, et al.
Publicado: (2016)

Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer
por: Broggini, Massimo, et al.
Publicado: (2013)

Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers
por: Atallah, Ghofraan Abdulsalam, et al.
Publicado: (2023)

ATR Inhibitors in Platinum-Resistant Ovarian Cancer
por: Li, Siyu, et al.
Publicado: (2022)

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
por: Havasi, Andrei, et al.
Publicado: (2023)

Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes
por: Ribeiro, Enilze, et al.
Publicado: (2013)

Platinum resistance in breast and ovarian cancer cell lines
por: Eckstein, Niels
Publicado: (2011)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
por: Indini, Alice, et al.
Publicado: (2021)

Cis dichlorodiammine platinum induced DNA interstrand cross-links in primary cultures of human ovarian cancer.
por: Balconi, G., et al.
Publicado: (1991)

Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
por: Guffanti, Federica, et al.
Publicado: (2020)

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
por: Flynn, Michael J., et al.
Publicado: (2022)

Lack of Efficacy: When Opioids Do Not Achieve Analgesia from the Beginning of Treatment in Cancer Patients
por: Corli, Oscar, et al.
Publicado: (2019)

Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer
por: Yang, Ling, et al.
Publicado: (2022)

Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives
por: Awada, Ahmad, et al.
Publicado: (2022)

Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
por: Gonzalez-Ochoa, Eduardo, et al.
Publicado: (2023)

Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
por: Chiappa, Michela, et al.
Publicado: (2022)

Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer
por: Leamon, Christopher P, et al.
Publicado: (2013)

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
por: McClung, E Clair, et al.
Publicado: (2016)

Exosomes as mediators of platinum resistance in ovarian cancer
por: Crow, Jennifer, et al.
Publicado: (2017)

Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy
por: Zhao, Chuchu, et al.
Publicado: (2017)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
por: Mantia-Smaldone, Gina M, et al.
Publicado: (2010)

Role of Jagged1/STAT3 signalling in platinum‐resistant ovarian cancer
por: Yang, Jiang, et al.
Publicado: (2019)

Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models()
por: Chilà, Rosaria, et al.
Publicado: (2017)

Decitabine reactivated pathways in platinum resistant ovarian cancer
por: Fang, Fang, et al.
Publicado: (2014)

Altered glutamine metabolism in platinum resistant ovarian cancer
por: Hudson, Chantelle D., et al.
Publicado: (2016)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy
por: Kang, Josephine, et al.
Publicado: (2012)

Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer
por: Luyckx, Mathieu, et al.
Publicado: (2014)

Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer
por: Tian, Hua, et al.
Publicado: (2019)

Recent Insights into Mucinous Ovarian Carcinoma
por: Ricci, Francesca, et al.
Publicado: (2018)

Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer
por: Ishibashi, Masumi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9gdvahfh9mh8cmj6osp17rama0